Ferrario Carlos M
Hypertension and Vascular Disease Center, Wake Forest University Health Science Center, Winston-Salem, NC 27157, USA.
Curr Hypertens Rep. 2003 Apr;5(2):129-34. doi: 10.1007/s11906-003-0069-y.
Increased understanding of the contribution of angiotensin peptides to the physiologic control of arterial pressure and cardiovascular regulation has been made possible with the introduction of agents that either inhibit the activity of angiotensins forming enzymes or block the action of the peptides at their specific receptor subtypes. This review highlights some of the lessons that have been learned from the study of the actions of angiotensin-(1-7) and its inter-relationship with other vasodilator mechanisms that modulate the control systems that determine blood pressure and tissue perfusion. The studies suggest that the renin-angiotensin system acts as a humoral mechanism for blood pressure control through the generation of several distinct forms of angiotensin peptides that may bind to diverse receptor subtypes.
随着能够抑制血管紧张素形成酶活性或阻断肽在其特定受体亚型上作用的药物的引入，人们对血管紧张素肽在动脉血压生理控制和心血管调节中的作用有了更深入的了解。本综述重点介绍了一些从血管紧张素-（1-7）作用研究及其与其他调节血压和组织灌注控制系统的血管舒张机制的相互关系中学到的经验教训。研究表明，肾素-血管紧张素系统通过产生几种不同形式的血管紧张素肽来作为血压控制的体液机制，这些肽可能与不同的受体亚型结合。
